Asian Hedge Fund Manager, Long Short Equity, Macro

David Mudd

Asian Hedge Fund manager based in HK/SG with over 20 years of experience managing Asian Long/Short Equity funds. Macroeconomic top-down analysis generates thematic investments that are further researched from the bottom-up. Research is supplemented with advanced technical analysis. 
Previous experience includes M&A with Morgan Stanley and CPA with Deloitte in NYC. Wharton MBA.

The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (August 2026)

CanSino Biologics(6185 HK): Price Surged - Worth a Shot !!

Cross Asset Strategy

<ul>
<li>The Hong Kong market has regained momentum and strength since bottoming in June.  The materials and healthcare sectors have outperformed this month, with gold's advance underpinning metals' outperformance.</li>
<li>Growth factor investing continues to lag, while large-cap stocks have had the highest Sharpe ratio over the last year.  Value and dividend yield factors have outperformed in the long-only space.</li>
<li>GenScript Biotech (1548 HK) broke out to new highs in August, surpassing its 2022 high.  The company has seen a surge in its mainland revenue over the last year.</li>
</ul>


The Hong Kong market has regained momentum and strength since bottoming in June.  The materials and healthcare sectors have outperformed this month, with gold's advance underpinning metals' outperformance.
Growth factor investing continues to lag, while large-cap stocks have had the highest Sharpe ratio over the last year.  Value and dividend yield factors have outperformed in the long-only space.
GenScript Biotech (1548 HK) broke out to new highs in August, surpassing its 2022 high.  The company has seen a surge in its mainland revenue over the last year.


Technically Speaking Breakouts & Breakdowns - HONG KONG (August 2026)